Jesús M. Hernández-Rivas, MD, PhD

Research Interests: The molecular characterization of tumoral cells from hematological malignancies (chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes), the application of CRISPR/Cas9 in the study of blood disorders, and the integration of genomic high-throughput technologies for the study of cancer

Prof. Hernández-Rivas is Professor of the Department of Medicine of the University of Salamanca in Spain, senior hematologist at the Hospital Universitario de Salamanca and Head of the Research Groups in Molecular Cytogenetics at the Biomedical Institute of Research of Salamanca (IECSCYL-IBSAL), and Cancer Research Centre (CIC).

For more than three decades, Prof. Hernández-Rivas has been the leader of the Oncology Cytogenetics Unit (UCO) in the Hematology Service of the University Hospital of Salamanca, which is the reference center for studies of molecular cytogenetics in the Community of Castilla y León, Aragon, Extremadura, and Andalucía.

Prof. Hernández-Rivas has published over 293 articles in international scientific journals, and directed 49 research projects and 20 doctoral theses. In addition, he has been a member of the executive committee of the Concerted Action funded by the Marie-Curie Foundation "CGH Arrays and Molecular Cytogenetics", as well as of several scientific committees and advisors, participating in the organization of I+D+I activities. He has also been a member of the editorial board of the journal Cancer Genetics and Cytogenetics, editor of the journal "Continuing Education in Hematology and Hemotherapy”, and coordinator of the Doctorate program with a mention of quality "Advances in Internal Medicine".

Prof. Hernández-Rivas has been involved in many national and international research projects, such as MILE ("Microrarrays Innovations in Leukemia", IRON “Interlaboratory Robustness of Next-generation sequencing”, and NGS-PTL "Next Generation Sequencing Platform for Personalized Therapy for Leukemia" program of FP7- HEALTH-2012 INNOVATION-1.

At present, he is the Project Coordinator of the Project HARMONY PLUS “Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS” (Grant agreement 945406) approved by the Innovative Medicines Initiative (IMI2), which is part of the Big Data for Better Outcomes initiative (BD4BO) of the Horizon 2020 projects. HARMONY PLUS continues the HARMONY’s work, a European Network of Excellence that captures, integrates, analyses, and harmonizes Big Data from high quality multidisciplinary sources for the purpose of acquiring valuable knowledge across the spectrum of hematologic malignancies. The aim of HARMONY PLUS is to build on HARMONY’s work, adding additional blood cancers to the list of diseases under study and turning the existent HARMONY platform into an integrated services platform that will improve clinical decision making and clinical trial design. He is also the project coordinator of the ERA PerMed project SYNtherapy “SYNthetic Lethality for Personalized Therapy-based Stratification in Acute Leukemia”. Moreover, he currently leads another European project: NEMHESYS “NGS Establishment in Multidisciplinary Healthcare Education SYStem” (an Erasmus+ project) and participates in oncNGS, a H2020 project that aims at developing novel affordable NGS solutions both for solid and hematological tumors.

Prof. Hernández-Rivas’ group works on the molecular characterization of tumoral cells from hematological malignancies (chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes), the application of CRISPR/Cas9 in the study of blood disorders, and the integration of genomic high-throughput technologies for the study of cancer.

According to Scopus metrics, he published over 300 papers, receiving more than 13,000 citations and having a H-idex of 55 (April, 2022).

ORCID: 0000-0002-9661-9371

Scopus Author ID: 6602177131

WEB of Science Researcher ID: B-5459-2017

Editorial Board
Terms of Appointment: July 2022 - June 2024